US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Stage II and III ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026 ...

Phase 1 and 3 trials demonstrated improved survival rates, with new treatment strategies for EGFR-mutated NSCLC, HER2+ breast cancer, and small-cell lung cancer. AI innovations, such as the ASCO ...

Reader Bites celebrates dishes, drinks, and atmospheres from the Chicagoland food scene. Have you had a recent food or drink experience that you can’t stop thinking about? Share it with us at ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

The guideline update included 26 specific recommendations grouped in the overarching topics of discussions about infertility risk, risk for infertility with anticancer treatment, FP for men, FP for ...

IOVA's data at ASCO hit home the strength of Amtagvi long term, with five-year data noting a third of responses to Amtagvi in melanoma remain ongoing after five years despite no additional treatment.

Reporting on studies in early breast cancer presented at ASCO 2025, Dr Ian Krop of Yale Cancer Center discusses potential refinements in treatment across all subtypes as well as a significant study in ...

Petros Grivas, MD, shares key updates from ASCO 2025, focusing on advances in prostate cancer across disease stages. He highlights promising results from the AMPLITUDE trial showing a radiographic ...

Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting. Dr. Joshua K. Sabari and Dr. Nausheen Ahmed sat ...